PharmEasy - Unlisted Shares
Fundamentals
- Current Price
- ₹8
- Market Cap
- ₹6,078.51 Cr
- ISIN
- INE0DJ201029
- Face Value
- ₹1
- EPS
- ₹-3.44
- P/B Ratio
- 3.70
- Book Value
- ₹2.62
- Debt / Equity Ratio
- 1.89
Key Financials
Profit & Loss
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue from Operations | 513.75 | 855.77 | 5728.82 | 2335.27 |
| Growth % | -39.97% | -85.06% | 145.32% | 0 |
| Operating Expenses | 936.8 | 1775.17 | 8074.54 | 2904.60 |
| Growth % | -47.23% | -78.02% | 177.99% | 0 |
| Operating Profit | -423.1 | -919.40 | -2345.72 | -569.33 |
| Op. Profit Margin % | -82.35% | -107.44% | -40.95% | -24.38% |
| Other Income | 545.48 | 567.48 | 52.18 | 25.39 |
| Finance Costs | 541.81 | 441.21 | 258.26 | 43.43 |
| Depreciation | 10.7 | 24.37 | 158.79 | 32.90 |
| Share to the associates | 0.00 | 0.00 | 0.66 | 0.00 |
| Exceptional items | 1726.97 | 4467.79 | -1260.84 | 0.00 |
| Profit Before Tax | -2,157.062 | -5,285.281 | -3,970.77 | -620.27 |
| Tax | 0.00 | 0.00 | 21.73 | 21.07 |
| Tax % | 0.00% | 0.00% | -0.55% | -3.40% |
| Discontinued Operations | 0.00 | -85.37 | 0.00 | 0.00 |
| Profit After Tax | -2,157.06 | -5370.65 | -3992.496 | -641.34 |
| Growth % | 59.84% | -34.52% | -522.53% | 0 |
| PAT % | -419.87% | -627.58% | -69.69% | -27.46% |
| Diluted EPS | -3.44 | -0.14 | -7.28 | -2.67 |
Company Financials
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Equity Capital | 624.04 | 614.20 | 614.20 | 25.62 |
| Reserves | 1,633.88 | 1029.94 | 6408.28 | 3555.56 |
| Total Equity | 2257.92 | 1644.15 | 7022.48 | 3581.18 |
| Borrowings | 1,979.81 | 3113.24 | 100.07 | 232.15 |
| Provision | 1.23 | 0.92 | 12.95 | 14.68 |
| Other Non-Current Liabilities | 10.19 | 596.99 | 501.23 | 101.13 |
| Total Non Current Liabilities | 1991.24 | 3711.15 | 614.24 | 347.96 |
| Borrowings | 1346.57 | 0.00 | 2485.35 | 353.24 |
| Other Current Liabilities | 714.45 | 5.02 | 1276.25 | 622.98 |
| Total current Liabilities | 2,061.02 | 188.21 | 3761.61 | 976.21 |
| Equity + Liabilities | 6310.18 | 5543.50 | 11398.33 | 4905.34 |
| Fixed Assets (incl. WIP) | 14.27 | 48.10 | 430.97 | 61.62 |
| Other Non Current Assets | 4460.00 | 4793.85 | 8465.15 | 3525.61 |
| Total Non Current Assets | 4474.28 | 4841.95 | 8896.12 | 3587.23 |
| Trade Receivables | 40.788 | 49.79 | 860.85 | 358.29 |
| Cash & Cash Equivalents | 1376.50 | 55.07 | 329.22 | 323.18 |
| Other Current Assets | 418.61 | 596.70 | 1312.14 | 636.65 |
| Total Current Assets | 1835.90 | 701.56 | 2502.21 | 1318.11 |
| Total Assets | 6310.18 | 5543.50 | 11398.33 | 4905.34 |
Shareholding Pattern
- Naspers Ventures BV
- 13.24%%
- Macritchie Investments Pte. Ltd
- 11.93%%
- Surbhi Singh jointly with Universal Trustees Private Limited
- 6.10%%
- TP G Growth V SF Markets Pvt Ltd
- 7.32%%
- Evermed Holdings Pte. Ltd
- 6.45%%
- Others
- 54.96%%
Strengths & Weaknesses
Strengths
- Focus on Quality and Customer Experience:25 out of 30 diagnostic labs are NABL (National Accreditation Board for Testing and Calibration Laboratories)accredited, representing the top 2% of all labs in India.Enhanced service levels and targeting high-value customers increased customer satisfaction.
- Strategic Initiatives for Margin Enhancement:Optimized product mix with a focus on higher-margin private label products.Adjusted sales mix to prioritize high-margin opportunities
- Cost Optimization:Rationalized workforce and operational costs, including significant reductions in marketing expenses.Optimized working capital through inventory and receivables management.
- Technological Advancements:Developed AI/ML-powered tools for inventory management and customer engagement.Integration of operational systems across the supply chain for improved efficiency.
- Sustainable Revenue Growth:Efforts to improve wallet share in existing chemist and hospital businesses.Increased customer retention and enhanced order value metrics.
- Global Expansion:Entered the Tanzanian market through a joint venture, demonstrating international growth ambitions.
Weaknesses
- Financial Losses:Significant losses reported for the fiscal year, although reduced from the prior year.High exceptional expenses, including impairment charges and redemption costs
- Dependence on External Capital:Reliance on rights issues and preference share allocations for funding operations and debt settlements.
- Declining Revenue:Consolidated revenue dropped by 14.7%, reflecting challenges in scaling certain operations.Reduced marketing spends led to lower new customer acquisition
- Operational Constraints:High dependency on working capital availability affected sales growth in key segments like hospitals and chemists
About PharmEasy
API Holdings Limited is a healthcare-focused organization that integrates technology and innovation to provide a comprehensive suite of healthcare services. Headquartered in Mumbai, India, the company is recognized for its flagship brands, such as PharmEasy and Thyrocare Technologies, which serve diverse sectors within the healthcare ecosystem, including diagnostics, pharmaceuticals, and retail distribution.The company operates across two primary business segments:
Board of Directors
- Siddharth Shah - Co-founder and CEO
- Dr. Dhaval Shah - Co-founder
- Siddharth Bhaskar Shah - Managing Director
- Harsh Shailesh Parekh - Wholetime Director
- Dharmil Nirupam Sheth - Wholetime Director
- Aditya Puri - Director
Senior Management
- Siddharth Shah - Co-Founder, Managing Director and Chief Executive Officer
- Dharmil Sheth - Co-Founder and Whole-time Director
- Dr. Dhaval Shah - Co-Founder
- Harsh Parekh - Co-Founder and Whole-time Director
- Hardik Dedhia - Co-Founder
